hemophilia A

Also found in: Medical, Encyclopedia, Wikipedia.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.hemophilia A - hemophilia caused by a congenital deficiency of factor VIII; occurs almost exclusively in men
bleeder's disease, haemophilia, hemophilia - congenital tendency to uncontrolled bleeding; usually affects males and is transmitted from mother to son
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
References in periodicals archive
Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
Patients suffering from hemophilia A has a mutation for factor VIII in the gene and patients suffering from hemophilia B have a mutation due to the absence of clotting factor IX.
The "Hemophilia Market Analysis By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment (On-demand, Prophylaxis), By Therapy (Replacement Therapy, Immune Tolerance Induction [ITI]Therapy, Gene Therapy), And Segment Forecasts to 2024" report has been added to ResearchAndMarkets.com's offering.
[ClickPress, Thu Jul 04 2019] Manufacturers such as Roche has recently acquired Spark Therapeutics for its long term investment hemophilia A gene therapy market.
There are two types of diseases like hemophilia A and hemophilia B, he said adding that the disease can transform into boy babies from their mothers.
M2 PHARMA-February 4, 2019-Chugai's Hemlibra Gains Positive CHMP Opinion in Severe Hemophilia a Without Inhibitors
is the number of live male births diagnosed with hemophilia A.
M2 EQUITYBITES-September 3, 2018-Bayer passes US FDA's approval for Jivi for the routine prophylactic treatment of hemophilia A
Global Banking News-September 3, 2018-Bayer passes US FDA's approval for Jivi for the routine prophylactic treatment of hemophilia A
Patients with known bleeding disorders other than Hemophilia A, liver disease, co morbid and using aspiring were excluded from the study.
Genentech, a member of the Roche Group, announced that pivotal data from the Phase III HAVEN 3 study, which evaluated HEMLIBRA prophylaxis administered every week or every two weeks in adults and adolescents aged 12 years or older with hemophilia A without factor VIII inhibitors, were published in the August 30, 2018, issue of the New England Journal of Medicine.
Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.